Log in or Sign up for Free to view tailored content for your specialty!
Cell Therapy News
FDA clears application for CAR gamma-delta T-cell therapy for advanced lymphoma
The FDA cleared an investigational new drug application for ADI-001, a an allogeneic chimeric antigen receptor gamma-delta T-cell therapy for the treatment of relapsed or refractory non-Hodgkin lymphoma.
CRISPR-edited allogeneic CAR-T demonstrates activity in advanced lymphoma
CTX110 exhibited clinical activity among patients with advanced B-cell lymphoma, according to topline data from a phase 1 dose-escalation trial released by the agent’s manufacturer.
Log in or Sign up for Free to view tailored content for your specialty!
CAR-T viewed as ‘pinnacle’ of immunotherapy for advanced ALL
Chimeric antigen receptor T-cell therapies are the apex of a practice-changing shift in the treatment of acute lymphoblastic leukemia, according to a presenter at NCCN 2020 Virtual Congress: Hematologic Malignancies.
MD Anderson, Allogene partner on development of allogeneic CAR T-cell therapies
The University of Texas MD Anderson Cancer Center announced a new commercial development partnership with San Francisco-based biopharmaceutical company Allogene Therapeutics.
CAR-T-associated cardiac toxicity ‘limited and reversible’ in younger patients with ALL
Cardiovascular toxicity associated with chimeric antigen receptor T-cell therapy is both limited and reversible among high-risk children and young adults with acute lymphoblastic leukemia, according to results of a phase 1 clinical trial.
CAR T-cell therapy shows vaccine effect in child with advanced sarcoma
The prognosis typically is poor for patients with metastatic rhabdomyosarcoma.
NiCord improves efficacy of bone marrow transplant for hematologic malignancies
A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.
FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma
The FDA granted orphan drug designation to oNKord, an investigational natural killer cell-based therapy, for the treatment of multiple myeloma, according to the agent’s manufacturer.
NCI scientist receives Samuel D. Gross Prize for surgical research
Renowned cancer researcher Steven A. Rosenberg, MD, PhD, has been awarded the 2020 Samuel D. Gross Prize for surgical research.
Cell therapy safe, feasible in anthracycline-induced cardiomyopathy
Transendocardial administration of allogenic bone marrow-derived mesenchymal stromal cells may benefit patients with anthracycline-induced cardiomyopathy, according to a phase 1 study.